Compare AMN & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMN | SLN |
|---|---|---|
| Founded | 1985 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Assisted Living Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.0M | 678.0M |
| IPO Year | 2001 | 2010 |
| Metric | AMN | SLN |
|---|---|---|
| Price | $34.32 | $13.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $22.25 | ★ $42.60 |
| AVG Volume (30 Days) | 701.8K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.58 | N/A |
| EPS | ★ 2.11 | N/A |
| Revenue | ★ $1,988,454,000.00 | $559,000.00 |
| Revenue This Year | $17.27 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.49 | ★ N/A |
| Revenue Growth | ★ 4.53 | N/A |
| 52 Week Low | $14.97 | $4.19 |
| 52 Week High | $37.22 | $17.58 |
| Indicator | AMN | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 57.07 |
| Support Level | $30.33 | $5.24 |
| Resistance Level | $36.41 | $17.58 |
| Average True Range (ATR) | 2.00 | 1.01 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 62.55 | 37.82 |
AMN Healthcare Services Inc provides healthcare workforce solutions and staffing services in the United States. Its comprehensive suite of talent solutions provides management, staffing, recruitment, language services, technology, predictive and market analytics, and related services to build and manage all or parts of the clients' healthcare workforce needs. Its reportable segments are: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. A majority of its revenue is generated from the Nurse and Allied Solutions segment, which includes the company's travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, and allied staffing (including revenue cycle solutions) businesses.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.